Pinned Tweet
Amazed to be part of this wonderful community of lung research enthusiasts 🫁 #WCLC25 @ChristianRolfo @FCappuzzo @DeboraBrascia @RobertoBoreaMD @MehmetAltanMD @Al3ssandroRusso @marinagarassino @fede_pezz86 and many others ⭐️
Claudia PARISI, MD retweeted
Important new study in BMJ Oncology
Does loneliness increase cancer mortality?
🔹 Loneliness or social isolation increased all-cause mortality by 34% and cancer-specific mortality by 11%
💬 Sometimes it’s not metastasis that kills — it’s silence. Loneliness is oncology’s invisible prognostic factor...
bmjoncology.bmj.com/content/…
Claudia PARISI, MD retweeted
Thank you, Claudia @ClaudiaParisi18 , for these 4 years with us at @GustaveRoussy You have been an invaluable help to the team and our Lung pts. Thank you for your unwavering work and the Italian cheerfulness you brought us. Wishing you all the very best for your future in Nice!
Claudia PARISI, MD retweeted
📗 Major advances in the systemic treatment of NSCLC have been made over the past 20 years. CANCER delivers 8 comprehensive reviews on targeted therapies for NSCLC written by leading global experts in this recent supplement: acsjournals.onlinelibrary.wi…
@OncoAlert #LCSM
Coming soon at #ESMO25 our study on gender disparities in RPM and SDH across cancer pts in 110 centres
@Resiliencecare @barlesi @GustaveRoussy
My research is now moving towards digital solutions exploitation to study and mitigate gender-related BiAbs tox experience in NSCLC.
5
374
Claudia PARISI, MD retweeted
🔥Congratulations🎊
🎖️ @IASLC Academy Mentors & Participants🌟
👥 @RManochakian @ChristianRolfo @maraantonoff @JairBar4 @JessicaJLinMD @triparnasen @acmoorephd @ZerAlona @fabiomoraesmd @ElinardouHelena @BalazsHalmosMD @LuisRaezMD @Piuchagarrido and more
@OncoAlert #LCSM #WCLC25
🗺️ #WCLC25 @IASLC #BARCELONA🇪🇸
📅 Sept. 6–9, 2025
🔽🔽🔽🔽🔽
🔥#WCLC25 Mobile📱App Released🆙
🌐 wclc.iaslc.org/mobile-app-gu…
🔼🔼🔼🔼🔼
👥Conference Chairs🌟
@UmbertoMalapel1 @DrJNaidoo @NReguart @IsaOpitz
#LCSM @OncoAlert @Larvol
Claudia PARISI, MD retweeted
I'm happy to share our new publication 📝 : jamanetwork.com/journals/jam…
In this cohort study, including more than 40,000 patients with #NSCLC
At immunotherapy start, we found a association between survival and prescription of : Antibiotic, PPI &High dose of steroid
@BenjaminBesseMD
Need to implement gender-informed RPM strategies towards
cancer care equity.
Come and visit our poster at row 25
#WCLC25 @barlesi @GustaveRoussy @ines_vazluis @Resiliencecare
Being selected as a participant in the 2025 IASLC Academy has been a unique opportunity to advance my professional path within an international community of leaders and mentees in the field of thoracic oncology! Amazed by this exciting experience 💫
🚨🔥The future of #ThoracicOncology is in GREAT hands!
The 2025 @IASLC #Academy Workshop (& final meeting) with OUTSTANDING group of #EarlyCareer #Physicians & #Researchers at #WCLC25.
Honored to serve as academy co-chair with my amazing friend @ChristianRolfo & GREAT faculty.
10
641
MTAP expression by immunohistochemistry: a novel biomarker in non-small cell cancer of the lung - Journal of Thoracic Oncology jto.org/article/S1556-0864%2…
1
291
In Italy we have one of the most recognized hepatobiliary surgeon, well known for his contributions to liver surgery in the field of oncologic liver resection and minimally invasive techniques.
I met him and I was very impressed from his humanity, kindness and honesty 💎
Pleased to announce the release of another scaffold sparing solution for boosting one stage removal of multiple bilobar colorectal liver metastases: SLICED LIVER HEPATECTOMY
@HumanitasMilano @HUNIMED
@IHPBA @AHPBA @EAHPBA @APHPBA @IASGO_1988 @SSATNews @SocSurgOnc @Aicep4
1
290
Claudia PARISI, MD retweeted
Thanks #ASCO25 for the amazing opportunity to present some of the @GustaveRoussy works
@FAndreMD @barlesi @drcmassard @BenjaminBesseMD @dplanchard @BarbaraPistill2 @EmelineColomba @JordiRemon @HollebecqueA @Ribeiro2M @MichelsJudith @derosa__lisa and many more !
FRONT-BRAF: 1L immunotherapy +/- chemo vs. BRAF + MEK inhibitors in mNSCLC presented by my friend and colleague @DiFedericoMD a very kind-hearted, dedicated thoracic oncologist with a bright future ahead 🌟 🇮🇹 🇺🇸 #ASCO25 youtu.be/WgSUjS7xRJQ?si=KCV8… via @YouTube
Claudia PARISI, MD retweeted
Pleasure to see @MarcelloTiseo at #ASCO2025 presenting the ALNEO academic study by the @GOIRC2015 group and making the whole 🇮🇹 thoracic oncogy community proud!
@ASCO @ALKpositiveINT – at Chicago, IL
I was in specialist training when we run ph1 trial with tarlatamab at @GustaveRoussy (2022). #asco2025: ph3 + results ✅ EXCELLENT news for our SCLC pts. 1st aim of our careers (within and outside clinical trials): improve pts outcomes
#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC :
✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001
✅ improved QoL (dyspnea and cough)
✅ 27% vs 62% G3 TRAEs
Grateful to all collaborators, @Amgen science team and above all our pts
Impact de la supplémentation orale en Akkermansia muciniphila dans le cancer du rein (RCC) , essai ev2101
Présenté par Dr @derosa__lisa @GustaveRoussy
🕰️ Chronobiological mechanisms matter in ICI efficacy. First randomised clinical trial demonstrating improvement in ORR, PFS, OS in the Early Time-of-Day (ToD) arm 🧬 great effort by Francis Lévi from @ParisSaclay #ASCO2025
Claudia PARISI, MD retweeted
Replying to @DiFedericoMD
@DiFedericoMD presenting our collaborative study on 1st line BRAF/MEKi vs. #ICI for mNSCLC at #ASCO2025.
⬆️ OS with #ICI particularly in pts w/ PDL1 >1%, h/ tobacco use & TP53m. @ASCO @MarceloCorassa @mvnegrao @DanaFarber @MDAndersonNews @MSKCancerCenter
Claudia PARISI, MD retweeted
Stop by the #ASCO25 Poster Session to learn about targeted treatments for BRAF-mutated NSCLC🧬
📗Available in our Targeted Therapies in NSCLC supplement, this review illuminates how new treatments are improving outcomes:
acsjournals.onlinelibrary.wi…
@OncoAlert @dplanchard
Claudia PARISI, MD retweeted
🔹 Gustave Roussy at #ASCO25 🔹
Dr. Antoine Hollebecque, oncologist at @GustaveRoussy, presents a new combination of treatments for patients with colorectal #cancer in treatment failure at @ASCO.
Press release ➡ ow.ly/Ye0r50W1Z0X

















































